Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2023
2022
2021
2020
2019
2018
2017
2016

Nov 12 2021

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

Read More +

Nov 9 2021

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Read More +

Oct 22 2021

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types

Read More +

Oct 12 2021

Achilles Therapeutics to Join the Northern Alliance Advanced Therapy Treatment Centre Consortium

Read More +

Oct 1 2021

Achilles Therapeutics to Present at Upcoming Scientific Congresses

Read More +

Sep 2 2021

Achilles Therapeutics to Present at Upcoming Investor Conferences

Read More +

Aug 25 2021

Achilles Therapeutics Announces Grant of US and European Patents

Read More +

Aug 10 2021

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Read More +

Jul 1 2021

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

Read More +

Jun 4 2021

Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Read More +

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions